MEDICINA
Departamento
F.
Téllez Pérez
Publicaciones en las que colabora con F. Téllez Pérez (20)
2024
2022
-
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
JHEP Reports, Vol. 4, Núm. 5
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2021
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810
-
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response
AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2019
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 33, Núm. 2, pp. 269-278
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 32, Núm. 11, pp. 1423-1430
-
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLoS ONE, Vol. 13, Núm. 7
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
-
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
PLoS ONE, Vol. 11, Núm. 2
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
2014
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort
International Journal of Infectious Diseases, Vol. 26, pp. 83-87
2013
-
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study
BMC Infectious Diseases, Vol. 13, Núm. 1
2012
-
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis
Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478